HC Wainwright Reiterates "Buy" Rating for Tyra Biosciences (NASDAQ:TYRA)

HC Wainwright reiterated their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA - Free Report) in a research report report published on Monday morning,Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

A number of other research firms have also commented on TYRA. Oppenheimer lifted their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a research note on Thursday, September 19th. UBS Group started coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a "buy" rating and a $28.00 target price on the stock. Bank of America raised Tyra Biosciences from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. Finally, Wedbush reissued an "outperform" rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $30.50.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock traded down $0.36 during trading on Monday, reaching $14.84. The company's stock had a trading volume of 52,989 shares, compared to its average volume of 242,472. The business's fifty day moving average price is $15.45 and its 200-day moving average price is $19.20. The firm has a market cap of $750.95 million, a price-to-earnings ratio of -9.22 and a beta of 1.04. Tyra Biosciences has a one year low of $12.17 and a one year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.01). Sell-side analysts anticipate that Tyra Biosciences will post -1.57 EPS for the current year.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 27,493 shares of the business's stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $16.56, for a total value of $455,284.08. Following the transaction, the director now directly owns 458,506 shares of the company's stock, valued at $7,592,859.36. The trade was a 5.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alan Fuhrman bought 9,500 shares of Tyra Biosciences stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $152,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 12,849 shares in the company, valued at $205,584. This represents a 283.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 84,160 shares of company stock valued at $1,827,047. 15.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. American Century Companies Inc. boosted its holdings in shares of Tyra Biosciences by 582.9% in the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company's stock worth $2,723,000 after acquiring an additional 145,346 shares in the last quarter. Perceptive Advisors LLC raised its position in Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company's stock worth $16,108,000 after purchasing an additional 338,208 shares during the last quarter. Janus Henderson Group PLC bought a new position in Tyra Biosciences in the 3rd quarter worth approximately $24,994,000. Ensign Peak Advisors Inc bought a new position in Tyra Biosciences in the 2nd quarter worth approximately $3,047,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Tyra Biosciences in the 3rd quarter worth approximately $593,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.